Shared on17 Sep 25Fair value Increased 5.56%
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 1.29%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.85%
AnalystConsensusTarget has decreased profit margin from 4.8% to 3.1%, increased future PE multiple from 26.9x to 41.4x and decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.